The role of HBV quasispecies diversity& other factors in residual HBV viremia on TDF-based cART
Background: Tenofovir (TDF) is effective in suppressing HIV and HBV replication in HIV-HBV co-infection. HBV DNA can persist in some individuals on TDF-based combination antiretroviral therapy (cART) but HBV resistance to TDF has not been reported to date. We initiated this study to determine risk factors associated with detectable HBV DNA beyond 6 months on…